Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET
Company Participants
David Nakasone – Head, IR
Bobby Azamian – Chairman & CEO
Aziz Mottiwala – Chief Commercial Officer
Jeff Farrow – CFO and CSO
Sesha Neervannan – COO
Elizabeth Yeu – Chief Medical Officer
Conference Call Participants
Eddie Hickman – Guggenheim Securities
Lachlan Hanbury-Brown – William Blair
Andrea Newkirk – Goldman Sachs
Oren Livnat – HC Wainwright
Balaji Prasad – Barclays
Jason Gerberry – Bank of America Merrill Lynch
Corey Jubinville – Life Sci Capital
Francois Brisebois – Oppenheimer
Operator
Welcome to Tarsus’ Third Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded at this time, I would like to turn the call over to David Nakasone, Head of Investor Relations, to lead off the call. David, you may begin. Thank you.
David Nakasone
Before we begin, I encourage everyone to go to the investor section of the Tarsus website to view the earnings release and related materials we will be discussing today. Joining me on the call this afternoon, are Bobby Azamian, our Chief Executive Officer and Chairman, Aziz Mottiwala, our Chief Commercial Officer, Sesha Neervannan, our Chief Operating Officer, Jeff Farrow, our Chief Financial Officer and Chief Strategy Officer, and joining us for the first time, Dr Elizabeth Yeu, our newly appointed Chief Medical Officer for the Q&A portion.
I’d like to draw your attention to slide three, which contains our forward looking statements. During this call, we will be making forward looking statements that are based on our current expectations and beliefs, these statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional detail.
With that, I
Read the full article here
